A Board Member Bought Shares of Edwards Lifesciences Corp (EW)

A Form 4 filed with the SEC has disclosed that Wesley von Schack, a member of the Board of Directors at Edwards Lifesciences Corp (NYSE:EW), directly acquired 2,000 shares on April 26th at an average price of $64.95 per share. Edwards Lifesciences is a $7.3 billion market cap medical device company with a focus on cardiovascular therapy products such as heart valves. We track insider purchases because studies show that stocks bought by insiders exhibit a small outperformance effect (read our analysis of studies on insider trading); we think that this is because it is generally rational for insiders to sell shares in order to increase diversification, and so buying should signal some level of confidence in the stock.

In the first quarter of 2013, Edwards Lifesciences Corp (NYSE:EW) increased its revenue by 8% versus a year earlier. With cost of goods sold actually decreasing, the company experienced a 27% increase in pretax income if we ignore a large special gain during the quarter. Adjusted earnings per share slightly missed analyst expectations, but overall we’d still consider these to be good results.

At current prices Edwards Lifesciences Corp (NYSE:EW) trades at 20 times trailing earnings, so the market is already pricing in high growth for at least a short period. Wall Street analysts are not particularly optimistic; they do expect earnings per share to increase by a bit over the next couple years but consensus forecasts for 2014 give a forward P/E of 18- which we would still consider a valuation dependent on considerable improvements on the bottom line. The stock price has fallen 23% in the last year against a rising market as investors have become less confident in the company, potentially instigating von Schack into buying these shares.

SAC CAPITAL ADVISORS

We track quarterly 13F filings from hedge funds and other notable investors to help us with our work developing investment strategies (we have found, for example, that the most popular small cap stocks among hedge funds earn an average excess return of 18 percentage points per year) and can use our database to see which filers owned Edwards at the beginning of this year. We can see that Sectoral Asset Management was the only filer we track which owned over $20 million of the stock at the end of December; Sectoral’s 13F shows it owning 1.4 million shares (find Sectoral’s favorite stocks). Billionaire Steve Cohen’s SAC Capital Advisors initiated a position of about 170,000 shares during Q4 (see Cohen’s stock picks).

Peers for Edwards Lifesciences Corp (NYSE:EW) include Medtronic, Inc. (NYSE:MDT), St. Jude Medical, Inc. (NYSE:STJ), Baxter International Inc. (NYSE:BAX), and Becton, Dickinson and Co. (NYSE:BDX). All four of these peers trade within a range of 13 to 17 times their trailing earnings, meaning that Edwards is valued at a premium relative to similar companies. Generally low growth is expected at these peers as well, and so all four are cheaper than Edwards on a forward earnings basis as well. However, recent financial performance has been lackluster: St. Jude actually reported a decline in revenue in its most recent quarter compared to the same period in the previous year, with the other three businesses seeing no more than a 4% increase on the top line.

We are skeptical that Edwards Lifesciences Corp (NYSE:EW) can continue to grow its pretax income at the high rates it did in Q1 without higher revenue growth as well, and so even with the insider purchase we are doubtful that the stock is a good value. The company actually does not look too expensive compared to its peers, demonstrating at least moderate increases in sales while the other four businesses we looked at struggled to some degree. However, we would conclude that the industry as a whole does not appear to be a good source of value rather than that there is some case for Edwards Lifesciences Corp (NYSE:EW) on that basis.

Disclosure: I own no shares of any stocks mentioned in this article.

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

The 10 Most Peaceful Countries in the World

5 Big Reasons Communism Failed

The 15 Most Famous Carl Icahn Quotes

10 Scary Animals that are Actually Harmless

The 8 Most Famous Singer-Actors in Entertainment

The 10 Longest Wars of All Time

The 13 Worst Looking Foods that Taste Great

The 6 Most Gruesome Injuries Suffered During a Sports Match

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!